10-(4-氯苯基)-7-硝基嘧啶并[4,5-b]喹啉-2,4(3H,10H)-二酮 | 317326-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 10-(4-氯苯基)-7-硝基嘧啶并[4,5-b]喹啉-2,4(3H,10H)-二酮
• 英文名称: 10-(4-chlorophenyl)-7-nitro-10H-pyrimido[4,5-b]quinoline-2,4-dione
• 英文别名: 10-(4-Chlorophenyl)-7-nitropyrimido[4,5-b]quinoline-2,4-dione
• CAS: 317326-91-3
• 化学式: C₁₇H₉ClN₄O₄
• mdl: MFCD01630071
• 分子量: 368.736
• InChiKey: NGFVSPNFZJSTPT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  1
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  108
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  6-(4-chlorophenylamino)-1H-pyrimidine-2,4-dione 、 2-氯-5-硝基苯甲醛 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以52%的产率得到10-(4-氯苯基)-7-硝基嘧啶并[4,5-b]喹啉-2,4(3H,10H)-二酮
  参考文献：
  名称：

  Synthesis of 5-deazaflavin derivatives and their activation of p53 in cells

  摘要：

  A family of 5-deazaflavin derivatives has been synthesised using a two-step convergent strategy. The biological activity of these compounds was evaluated in cells, by assessing their ability to stabilize and activate p53. These compounds may act as low molecular weight inhibitors of the E3 activity of HMD2 in tumours that retain wild-type p53. Importantly, we have demonstrated that the nitro group present in all three of the original lead compounds [1-3 (HL198C-E)] is not essential for observation of this biological activity. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2006.10.011

文献信息

• Deazaflavin compounds and methods of use thereof
  申请人：Weissman M. Allan

  公开号：US20060211718A1

  公开（公告）日：2006-09-21

  The present invention features 5-deazaflavin compounds, pharmaceutical compositions of 5-deazaflavin compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more 5-deazaflavin compounds of the invention.

  本发明的特征是5-去氮黄素化合物、5-去氮黄素化合物的药物组合物和治疗癌症患者的方法，该方法包括给患者服用一种或多种本发明的5-去氮黄素化合物。
• 5-Deazaflavin derivatives as inhibitors of p53 ubiquitination by HDM2
  作者：Michael P. Dickens、Patricia Roxburgh、Andreas Hock、Mokdad Mezna、Barrie Kellam、Karen H. Vousden、Peter M. Fischer

  DOI：10.1016/j.bmc.2013.09.038

  日期：2013.11

  Based on previous reports of certain 5-deazaflavin derivatives being capable of activating the tumour suppressor p53 in cancer cells through inhibition of the p53-specific ubiquitin E3 ligase HDM2, we have conducted an structure-activity relationship (SAR) analysis through systematic modification of the 5-deazaflavin template. This analysis shows that HDM2-inhibitory activity depends on a combination of factors. The most active compounds (e. g., 15) contain a trifluoromethyl or chloro substituent at the deazaflavin C9 position and this activity depends to a large extent on the presence of at least one additional halogen or methyl substituent of the phenyl group at N10. Our SAR results, in combination with the HDM2 RING domain receptor recognition model we present, form the basis for the design of drug-like and potent activators of p53 for potential cancer therapy. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
• DEAZAFLAVIN COMPOUNDS AND METHODS OF USE THEREOF
  申请人：THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES

  公开号：EP1633749A2

  公开（公告）日：2006-03-15
• HIGHLY SOLUBLE PYRIMIDO-DIONE-QUINOLINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
  申请人：Weissman Allan

  公开号：US20100056549A1

  公开（公告）日：2010-03-04

  The present invention features pyrimido-dione-quinoline compounds having improved solubility, pharmaceutical compositions of substituted pyrimido-dione-quinoline compounds and methods of treating a patient suffering from cancer, the method comprising administering to a patient one or more pyrimido-dione-quinoline compounds of the invention.
• COMPOSITIONS AND METHODS FOR TREATING DISEASE STATES ASSOCIATED WITH ACTIVATED T CELLS AND/OR B CELLS
  申请人：Children's Hospital Medical Center

  公开号：US20160022720A1

  公开（公告）日：2016-01-28

  Disclosed are combination therapies and related compositions that may contain one or more of a p53 potentiating agent, a DNA-damaging agent, an agent that inhibits cell cycle check point, and a pharmaceutically acceptable carrier. Also disclosed are methods of using such compositions for the treatment of conditions related to T cell and/or B cell activation in subjects in need of such treatment.